Company Invited to Particpate in Strategic US
Investor Conference
TORONTO, July 9, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN),
(OTCQB: KHRNF), (Frankfurt:
A2JMZC), a cannabis company with core operations in Latin
America, announced today that the Company will be presenting
at the 39th annual Canaccord Genuity Growth Conference, taking
place in Boston, MA, August 7-8, 2019.
Khiron CEO, Alvaro Torres will
present and answer questions from conference attendees, with
Company president Chris Naprawa also
in attendance for one on one meetings. A recording of the
presention will be available and posted on the Khiron website.
Hosted by Canaccord Genuity, the conference brings together over
1,300 attendees, institutional investors and financial leaders to
hear from growth companies, including in the health and life
sciences sector. Conference details can be found by visiting:
https://bit.ly/2Tg69rC
Recent Company Highlights
- Completes acquisition of Uruguay-based Nettagrowth International,
advancing multi- country operator strategy, and gaining entry to
Mercosur trading block
- Completes new lab facilities with initial capacity of 3 tonnes
of extract per year
- Expands Kuida® cosmeceutical brand distribution with
Colombian drugstore chain
- Joins U.S. National Cannabis Roundtable with John Boehner, former Speaker of the House of
Representatives
About Khiron
Khiron Life Sciences Corp. is positioned to be the dominant
integrated cannabis company in Latin
America. Khiron has core operations in Latin America and is fully licensed in the
country for the cultivation, production, domestic distribution, and
international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
the first Colombian based medical cannabis company to trade on any
exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at https://investors.khiron.ca/
To be added to the distribution list, please email
khiron@kcsa.com with "Khiron" in the subject line.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Further information in respect of the Company can be found
at www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-ceo-alvaro-torres-to-present-at-2019-canaccord-genuity-us-annual-growth-conference-300881136.html
SOURCE Khiron Life Sciences Corp.